Company Overview
Actuate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment of various cancers within the United States market. The company functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on early-stage research, development, and regulatory pathways for novel drug candidates rather than mature commercial products. As of the latest data, the firm maintains a market capitalization of $50.98M and employs a workforce of 12 individuals, reflecting a very small-scale organization typical of early-phase biotechnology ventures. This limited market cap and lack of reported revenue indicate that the company is currently in an investment-intensive phase where capital allocation is directed toward advancing its lead product candidate, elraglusib injection, through Phase 2 trials for metastatic pancreatic cancer, rather than generating commercial sales.
Financial Health
Actuate Therapeutics reports a net income of $-22,227,852 for the trailing twelve months, while both revenue and EBITDA are listed as N/A due to the company's pre-commercial status. The significant gap between the reported net loss and the absence of revenue highlights a cost structure dominated by research and development expenditures, clinical trial costs, and administrative overhead necessary to progress a clinical-stage asset. The company generated free cash flow of $-11,038,870 during the period, which signifies a heavy reliance on external capital sources such as equity offerings or debt financing to sustain operations without internal cash generation. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a standard characteristic for biotechnology firms that have not yet achieved product sales, indicating that current financial performance is driven by expenses rather than profitability. On the balance sheet, the company holds $13.16M in cash and has no reported debt, creating a scenario where liquidity assets vastly exceed liabilities. The debt-to-equity ratio is listed as N/A, reflecting the absence of debt obligations, which suggests a conservative capital structure free from leverage risk. Furthermore, the current ratio stands at 2.39, indicating that the company possesses sufficient liquid assets to cover its short-term obligations more than twice over. Return on Equity is reported at -553.7% and Return on Assets at -120.4%, metrics that reveal the company is currently destroying shareholder value through accumulation of losses rather than generating returns, a common trajectory for clinical-stage companies burning cash to achieve clinical milestones.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the company's lack of earnings, while the forward P/E is reported as -1.52, a negative figure that implies the market is pricing in continued losses or that traditional earnings-based valuation models are not applicable at this stage. The Price to Book ratio is 6.30, which indicates that the stock is trading at a significant premium relative to its net asset value, suggesting that the market places a high valuation on the potential future value of the elraglusib pipeline rather than current book assets. The Price to Sales and EV/EBITDA metrics are both N/A, which suggests that alternative valuation multiples relying on revenue or earnings generation cannot be utilized to assess the company's relative value against peers. The stock has traded within a 52-week range defined by a high of $11.99 and a low of $2.05, providing a historical context for price volatility over the past year. The Beta is listed as N/A, meaning there is no available data to quantify the stock's volatility relative to the broader market, though the wide range between the high and low suggests inherent instability common in small-cap biotechnology equities.
Growth & Income
Revenue Growth and Earnings Growth are both listed as N/A, which is consistent with a company that has not yet launched a commercial product to generate sales figures for year-over-year comparison. Since the company has no dividend yield or payout ratio, the financial profile indicates that the firm reinvests all available resources, including the $13.16M cash reserve, directly back into research and development to advance its clinical programs. The absence of dividend payments and the negative earnings growth trajectory confirm that the company prioritizes capital expenditure for pipeline advancement over returning value to shareholders in the form of income. Consequently, the overall growth and income profile is characterized by zero current income generation and a complete reliance on capital markets to fund future expansion and clinical trial completion.